A similar mechanism is also observed with finasteride, a 5-alpha reductase inhibitor used in the management of benign prostatic hyperplasia, where suppression of DHT synthesis in the prostate leads to diminished epithelial growth.132,133 Furthermore, glucosinolates may influence androgen receptor (AR) signaling by modulating pathways involved in receptor activation. This evidence concerns the gene AR and benign prostatic hyperplasia.